We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Disrupted Molecular Signaling Drives Cancer Metastasis

By LabMedica International staff writers
Posted on 24 Jan 2017
A malfunction in molecular signaling that continually activates Yes-associated protein (YAP) has been linked to the ability of metastatic cancer cells to break away from the extracellular matrix (ECM) and travel throughout the body.

In order to study the interaction between YAP and ECM, investigators at The Institute of Cancer Research had to solve the technical challenge caused by perturbations that affect cell shape and, indirectly, protein localization. More...
To this end they developed a method using single-cell image analysis and statistical models that exploited the naturally occurring heterogeneity of cellular populations.

The investigators then systematically deleted 950 individual genes in cancer cell lines to identify any that influenced YAP signaling. They reported in the January 5, 2017, online edition of the journal Cell Systems that the proteins beta-PIX and PAK2, were the drivers behind both YAP activation and cell-ECM adhesion turnover during cell spreading.

To examine how YAP's activity was controlled in cancer cells, the investigators worked with cultures of triple-negative breast cancer cells that were derived either from a primary tumor or from a metastatic site. They found that if the beta-PIX pathway was disabled in cells from the primary tumor, YAP failed to activate. In contrast, in cells taken from the site of metastasis, YAP did activate. This finding indicated that invasive cancer cells sustained high levels of YAP even when not bound to the surrounding matrix.

Senior author Dr. Chris Bakal, leader of the dynamical cell systems team at The Institute of Cancer Research, said, "Our research shows how cancer cells that have become invasive are able overcome the normal constraints on cell movement. Cancer cells that have spread around the body have a switch which is jammed on - allowing them to produce a molecule called YAP all the time. This allows them to keep growing and spreading throughout the body, ignoring the physical controls that would normally stop this happening. Understanding more about the physical processes which constrain and control the growth and movement of cells can open up exciting new avenues for cancer treatment, which may have been missed until now."


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.